[131I-therapy of Basedow's disease and nonimmunogenic hyperthyroidism]

Area of Science:

• Endocrinology
• Nuclear Medicine
• Thyroidology

Context:

• Thyrotoxicosis, encompassing Graves' disease and goiters, presents a significant clinical challenge.
• Radioactive iodine (131I) therapy is a common treatment modality for hyperthyroidism.
• Long-term efficacy and outcomes of 131I therapy require further elucidation.

Purpose:

• To evaluate the long-term efficacy of radioactive iodine (131I) therapy in patients with thyrotoxicosis.
• To assess treatment outcomes based on the type of thyroid condition (Graves' disease, diffuse goiter, nodular goiter).
• To determine factors influencing treatment success and the rate of hypothyroidism.

Summary:

• A study evaluated 315 thyrotoxicosis patients treated with 131I from 1977-1982, with 246 assessable.
• Single 131I treatment normalized thyroid function in 72% of nodular goiter, 61% of diffuse goiter, and 36% of Graves' disease patients.
• Repeated 131I treatments achieved normalization in nearly all patients, particularly those with Graves' disease, though immune thyrotoxicosis showed resistance. Prior treatments influenced outcomes. Hypothyroidism occurred in 4-15%.

Impact:

• 131I therapy is a viable and effective treatment for various forms of hyperthyroidism.
• Understanding treatment resistance in Graves' disease can guide therapeutic strategies.
• Identifying factors associated with hypothyroidism can improve patient management and monitoring.